Yubo International Biotech Limited

Equities

YBGJ

US9883661004

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 15:27:36 30/05/2024 BST			5-day change	1st Jan Change
0.845 ^USD	+8.33%		-9.63%	+181.67%

05-20	Yubo International Biotech Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-12	Yubo International Biotech Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Yubo International Biotech Limited Reports Earnings Results for the First Quarter Ended March 31, 2024

May 20, 2024 at 01:16 pm

Yubo International Biotech Limited reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 0.377296 million compared to USD 0.316667 million a year ago.

Latest news about Yubo International Biotech Limited

Yubo International Biotech Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	05-20	CI
Yubo International Biotech Limited Reports Earnings Results for the Full Year Ended December 31, 2023	04-12	CI
Yubo International Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-20	CI
Yubo International Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
Yubo International Biotech Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Yubo International Biotech Limited Reports Earnings Results for the Full Year Ended December 31, 2022	14/04/23	CI
Yubo International Biotech Limited Auditor Raises 'Going Concern' Doubt	13/04/23	CI
Yubo International Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	16/11/22	CI
Insider Sell: Yubo International Biotech	10/11/22	MT
Yubo International Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
Yubo International Biotech Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
Yubo International Biotech Limited Reports Earnings Results for the Full Year Ended December 31, 2021	15/04/22	CI
Yubo International Biotech Limited Auditor Raises 'Going Concern' Doubt	14/04/22	CI
Yubo International Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/11/21	CI
Yubo International Biotech Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021	20/08/21	CI
Yubo International Biotech Limited Reports Earnings Results for the First Quarter Ended March 31, 2021	24/05/21	CI
Yubo International Biotech Limited Changes Fiscal Year End from the Last Calendar Day of February to December 31	05/02/21	CI
Platinum International Biotech Co., Ltd acquired Yubo International Biotech Limited for approximately $380 million in a reverse merger transaction.	13/01/21	CI

Chart Yubo International Biotech Limited

Duration

Period

Chart Yubo International Biotech Limited

More charts

Company Profile

Yubo International Biotech Ltd, formerly Magna-Lab Inc, is a holding company primarily operating through its subsidiary. The Company focuses on the research and development and application of endometrial stem cells and offers its products and services under the brand VIVCELL. The Companyâs product offerings include healthcare products for respiratory system, skincare products, hair care products, healthy beverages and male and female personal care products. The Company also offers stem cell related services including cell testing and health management consulting services.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
YUBO INTERNATIONAL BIOTECH LIMITED	+181.67%	101M
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B

Other Biotechnology & Medical Research